Jun 15
|
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
|
Jun 15
|
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
|
Jun 15
|
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
|
Jun 15
|
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
|
Jun 12
|
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
Jun 10
|
Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand
|
Jun 10
|
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
|
Jun 9
|
Sanofi: Information concerning the total number of voting rights and shares - May 2025
|
Jun 9
|
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
|
Jun 9
|
Regeneron and Sanofi’s dupilumab shows promise in AD trial
|
Jun 9
|
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
|
Jun 9
|
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
|
Apr 25
|
Swiss Agree to Tariff Negotiations With Trump Administration
|
Apr 24
|
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
|
Apr 24
|
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
|
Apr 24
|
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
|
Apr 24
|
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
|
Apr 24
|
Sanofi stays on course amid tariff turmoil
|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|